These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 11549423)

  • 1. Bordetella pertussis fimbriae are effective carrier proteins in Neisseria meningitidis serogroup C conjugate vaccines.
    Reddin KM; Crowley-Luke A; Clark SO; Vincent PJ; Gorringe AR; Hudson MJ; Robinson A
    FEMS Immunol Med Microbiol; 2001 Aug; 31(2):153-62. PubMed ID: 11549423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger.
    Campagne G; Garba A; Fabre P; Schuchat A; Ryall R; Boulanger D; Bybel M; Carlone G; Briantais P; Ivanoff B; Xerri B; Chippaux JP
    Pediatr Infect Dis J; 2000 Feb; 19(2):144-50. PubMed ID: 10694002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulation and characterisation of Bordetella pertussis fimbriae as novel carrier proteins for Hib conjugate vaccines.
    Crowley-Luke A; Reddin K; Gorringe A; Hudson MJ; Robinson A
    Vaccine; 2001 May; 19(25-26):3399-407. PubMed ID: 11348704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of meningococcal polysaccharide conjugate vaccine that can elicit long-lasting and strong cellular immune response with hepatitis B core antigen virus-like particles as a novel carrier protein.
    Xu L; Li Z; Su Z; Yang Y; Ma G; Yu R; Zhang S
    Vaccine; 2019 Feb; 37(7):956-964. PubMed ID: 30655174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEG as a spacer arm markedly increases the immunogenicity of meningococcal group Y polysaccharide conjugate vaccine.
    Huang Q; Li D; Kang A; An W; Fan B; Ma X; Ma G; Su Z; Hu T
    J Control Release; 2013 Nov; 172(1):382-389. PubMed ID: 23511718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neisseria meningitidis serogroup C polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate.
    Fukasawa LO; Gorla MC; Schenkman RP; Garcia LR; Carneiro SM; Raw I; Tanizaki MM
    Vaccine; 1999 Aug; 17(23-24):2951-8. PubMed ID: 10462229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Mouse Immunogenicity Model for the Evaluation of Meningococcal Conjugate Vaccines.
    Arunachalam AB; Vile S; Rosas A
    Front Immunol; 2022; 13():814088. PubMed ID: 35126397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New meningococcal C polysaccharide-tetanus toxoid conjugate Physico-chemical and immunological characterization.
    Cuello M; Cabrera O; Martinez I; Del Campo JM; Camaraza MA; Sotolongo F; Pérez O; Sierra G
    Vaccine; 2007 Feb; 25(10):1798-805. PubMed ID: 17240485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide.
    Bartoloni A; Norelli F; Ceccarini C; Rappuoli R; Costantino P
    Vaccine; 1995 Apr; 13(5):463-70. PubMed ID: 7543714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salivary and Serum Antibody Response Against Neisseria meningitidis After Vaccination With Conjugate Polysaccharide Vaccines in Ethiopian Volunteers.
    Bårnes GK; Workalemahu B; Kristiansen PA; Beyene D; Merdekios B; Fissiha P; Aseffa A; Caugant DA; Naess LM
    Scand J Immunol; 2016 Aug; 84(2):118-29. PubMed ID: 27219622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Memory immune response generated in Cercopithecus aethiops against meningococcal polysaccharide serogroup C conjugate vaccine.
    Carmenate T; Guirola M; Alvarez A; Canaán L; González S; Caballero E; Menéndez T; Guillén G
    FEMS Immunol Med Microbiol; 2005 Feb; 43(2):133-40. PubMed ID: 15681142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
    Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
    Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality, immunogenicity and stability of meningococcal serogroup ACWY-CRM
    Beresford NJ; Martino A; Feavers IM; Corbel MJ; Bai X; Borrow R; Bolgiano B
    Vaccine; 2017 Jun; 35(28):3598-3606. PubMed ID: 28408122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
    Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.
    El Bashir H; Heath PT; Papa T; Ruggeberg JU; Johnson N; Sinha R; Balfour G; Booy R
    Vaccine; 2006 Mar; 24(14):2544-9. PubMed ID: 16417952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical studies on new proteins as carrier for glycoconjugate vaccines.
    Tontini M; Romano MR; Proietti D; Balducci E; Micoli F; Balocchi C; Santini L; Masignani V; Berti F; Costantino P
    Vaccine; 2016 Jul; 34(35):4235-4242. PubMed ID: 27317455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants.
    Rennels MB; Edwards KM; Keyserling HL; Reisinger K; Blatter MM; Quataert SA; Madore DV; Chang I; Malinoski FJ; Hackell JG; Paradiso PR
    Pediatr Infect Dis J; 2001 Feb; 20(2):153-9. PubMed ID: 11224833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure of a protective epitope reveals the importance of acetylation of
    Henriques P; Dello Iacono L; Gimeno A; Biolchi A; Romano MR; Arda A; Bernardes GJL; Jimenez-Barbero J; Berti F; Rappuoli R; Adamo R
    Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29795-29802. PubMed ID: 33158970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan.
    Huo Z; Sinha R; McNeela EA; Borrow R; Giemza R; Cosgrove C; Heath PT; Mills KH; Rappuoli R; Griffin GE; Lewis DJ
    Infect Immun; 2005 Dec; 73(12):8256-65. PubMed ID: 16299322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.